Compare Fubotv Inc (FUBO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Recursion Pharmaceuticals Inc — how do they compare? Fubotv Inc trades at $9.57 (market cap $1.06B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| FUBO | RXRX | |
|---|---|---|
Market Cap | $1.06B | $1.81B |
Sector | Technology | Health |
52-Week High | $54.72 | $6.79 |
52-Week Low | $8.09 | $2.84 |
Enterprise Value | $1.23B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.45, up 0.96% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q3 2026 revenue of $1.48 billion, beating expectations, and raised its full-year adjusted EBITDA outlook to $90–$100 million. Valuation ratios appear attractive with a P/E of 2.53 and P/S of 0.19, while recent leadership changes include the appointment of former Disney executive Alisa Bowen as CEO.
The outlook is positive as FUBO shows improving financials and strategic partnerships, but risks include persistent net losses and high debt. Analyst consensus is a Buy with a $15.33 price target, suggesting significant upside potential if profitability goals are met.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
